CompletedNCT04748887Updated Feb 10, 2021

Oxidative Stress Markers in COPD

An observational study in Role of Oxidative Stress in COPD, sponsored by Minia University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by Minia University · Observational

Study type: Observational
Model: Case-control
Time perspective: Cross-sectional
Enrollment: 70
Sex: All

Study summary

Background:Striking feature of Chronic obstructive pulmonary disease (COPD) is its inability to resolve after cigarette smoke exposure has ended, which has contributed to the possibility that the disease could also be driven by other endogenous causes, such as autoimmunity or chronic infection . Many of the pathogenetic pathways involved in COPD and its development tend to be driven by oxidative stress.

Conditions studied

Role of Oxidative Stress in COPD

Keywords

COPD , oxidative stress, Superoxide Dismutase

In context

Lead sponsor

Minia University is the lead sponsor of 356 studies on the registry; 115 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Sampling method: Probability sample

Study population

Forty subjects of COPD who are non-smokers or stopped smoking for more than 6 months Based on the Global Initiative for Chronic Obstructive Lung Disease guidelines, COPD was diagnosed.9 2- Thirty subjects of non smokers healthy control

Inclusion criteria

1-Forty subjects of COPD who are non-smokers or stopped smoking for more than 6 months Based on the Global Initiative for Chronic Obstructive Lung Disease guidelines, COPD was diagnosed.9 2- Thirty subjects of non smokers healthy control

Exclusion criteria

Exclusion Criteria:

Patients of:
1. Acute exacerbation, at the time of the study, of COPD.
2. Any obvious abnormal lung parenchymal lesions.
3. Lung cancer.
4. Congestive heart failure.
5. current smokers
6. Drugs e.g anti-inflammatory , steroids ,analgesics, insulin , antineoplastic, antipsychotic drugs in the previous 2 weeks before the study.

Study design

Observational model: Case-control
Time perspective: Cross-sectional
Enrollment: 70 participants (actual)
Target follow-up: 4 Weeks
Patient registry: Yes

Groups and cohorts

nonsmokers copd cases ,
Fourty subjects of COPD who are non-smokers or stopped smoking for more than 6 months
Other: oxidative stess markers
non smokers healthy control
Thirty subjects of non smokers healthy control
Other: oxidative stess markers

Interventions

Otheroxidative stess markers
markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
Also known as: Superoxide Dismutase (SOD) and Malondialdehyde (MDA)

What researchers measure

Primary outcomes

oxidative stress markers in non smokers COPD compared to healthy control
markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
Time frame: 1month

Study locations

1 site

Minia University Hospital
Multiple Locations, Minia 61691, Egypt

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04748887
Lead sponsor: Minia University
Responsible party: zainab hassan saeed (principle investigator ,faculty of medicine,department of chest diseases,Minia University, Minia University) — Principal investigator
First posted: Feb 10, 2021
Start date: Sep 1, 2018
Primary completion: Apr 1, 2019
Completion: Sep 1, 2019
Last update: Feb 10, 2021

Study contacts

zainab H Saeed, MD

principal investigator · MD chest diseases

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Minia University

Start the discussion